After releasing disappointing phase 3 data early last year and receiving a FDA rejection in August, shares of Portola Pharmaceuticals Portola Pharmaceuticals’ most advanced drugs in development are the factor Xa anticoagulant betrixaban and the factor Xa reversal agent AndexXa. In March, management reported betrixaban phase 3 trial data that left investors questioning the drug’s future.
Category: Healthcare Law
Two Day Seminar: FDA’s Medical Device Software Regulation Strategy…
Research and Markets has announced the addition of the “FDA’s Medical Device Software Regulation Strategy: 2-Day In-Person Seminar by Ex-FDA Official” conference to their offering. The growth of the medical software industry outpaces the design of FDA’s regulatory process.
article
After the company reported in December that a key late-stage drug had come up short in trials, a sharp sell-off caused Opko Health to finish the fourth quarter down 12.2%, capping a 7.5% loss for the year,according to S&P Global Market Intelligence . Opko Health is run by billionaire CEO Phillip Frost, and until recently, Frost has been very successful at commercializing clinical-stage drugs that he’s purchased for Opko Health at bargain prices.
Here’s Why Merrimack Pharmaceuticals Inc. Fell 47.3% in 2016
Investors in the cancer-focused biotech had to stomach a 47% decline during the year, according to data from S&P Global Market Intelligence . That was a far worse decline than the 17% pullback that was rung up by the First Trust NYSE Arca Biotech ETF As the chart above indicates, Merrimack’s stock gave its investors a wild ride during 2016.
Fresenius Medical Care Slumps After Patient-Aid Subpoena
Fresenius Medical Care AG fell the most in almost seven months after saying it had received a subpoena in the U.S. over premium-assistance programs that support dialysis patients on private insurance plans that can be more lucrative for providers. Fresenius said the U.S. Attorney for the District of Massachusetts is investigating its connections to the American Kidney Fund, which manages a patient-assistance program for the private plans.
Silicon Valley Cash Is Still Chasing Blood Despite Theranos Bust
Amid the collapse of Theranos Inc. last year, investors are betting that some of the disgraced blood-testing startup’s lofty medical goals might still have a kernel of promise — at other companies. Grail, a company backed by Bill Gates and Jeff Bezos, said on Thursday that it’s expecting to raise a record $1 billion on the promise of a blood test to detect early-stage cancer.
Amgen Wins Ban on Sanofi’s Praluent Cholesterol Drug Sales
Amgen Inc. won a court ruling blocking rivals Sanofi and Regeneron Pharmaceuticals Inc. from selling their cholesterol-lowering drug Praluent in the U.S. because it infringes Amgen’s patents covering a rival treatment. U.S. District Judge Sue Robinson in Delaware ordered Sanofi and Regeneron Thursday to halt Praluent sales for 12 years because the drug infringes patents on Amgen’s Repatha medication.
Amgen Wins Ban on Sanofi’s Praluent Cholesterol Drug Sales
Amgen Inc. won a court ruling blocking rivals Sanofi and Regeneron Pharmaceuticals Inc. from selling their cholesterol-lowering drug Praluent in the U.S. because it infringes Amgen’s patents covering a rival treatment. U.S. District Judge Sue Robinson in Delaware ordered Sanofi and Regeneron to halt Praluent sales for 12 years because the drug infringes patents on Amgen’s Repatha medication.
How Senator Rand Paul Would Replace Obamacare
Sen. Rand Paul (R-KY) weighs in on the Senate Democrats' push to block the Obamacare repeal. As the new Republican-controlled Congress moves forward with its goal of repealing the Affordable Care Act, the biggest question now is what will replace it.
Why Valero Energy, Ensign Group, and The Bancorp Slumped Today
Wednesday was another good day for the stock market, as major market benchmarks posted gains of between 0.25% and 1% to climb back within reach of new record levels. Many market participants focused on the release of the Federal Open Market Committee’s most recent meeting minutes, which didn’t have any major surprises that threatened the positive mood among investors.
Is It Too Late to Buy Exelixis Stock?
The stock’s 2016 performance made it one of the best-performing biotech stocks of the year. That’s great news for investors who jumped aboard the fast-moving Exelixis train early.
3 Under-the-Radar Biotech Stocks to Watch in 2017
You read plenty about the biggest biotechs on the market. But what about smaller biotechs that have a lot of potential? Akebia Therapeutics might not have huge market caps yet, but they have a lot going for them.
In an Ironic Twist, Obamacare Enrollment Hits an All-Time High
In less than three weeks, the sands of time will likely begin slipping away for the Affordable Care Act, which is more commonly known as Obamacare. The hallmark legislation passed by President Obama in March 2010 faces the likelihood that it’ll be heavily amended or repealed in its entirety soon after President-elect Trump takes office.
1 Worsening Problem That Obamacare Simply Can’t Cure
Despite its many criticisms, the Affordable Care Act has arguably been the closest thing to universal healthcare that Americans have ever seen. According to data from the Centers for Disease Control and Prevention, the uninsured rate in the U.S. fell from 16% in the quarter immediately preceding the implementation of the ACA, which is more affably known as Obamacare, to just 8.9% by mid-2016.
With S&P 500, Nasdaq Down, Dow Struggles for Gains
Stocks moved mostly lower on the final day of trading of 2016, but all three indices are poised to close 2016 with gains. Despite stocks moving mostly lower on the last day of the year, the Dow is expected to post a double-digit annual increase, its best in three years.
Seattle Genetics Plunges After Drug Studies Halted on Deaths
Seattle Genetics Inc. plunged the most in five years after U.S. regulators halted several early-stage blood cancer studies following the deaths of four patients who suffered from liver damage. The Food and Drug Administration halted the trials testing Seattle Genetics’s acute myeloid leukemia, or AML, therapy, called SGN-CD33A.
The 3 Biggest Risks for Pfizer in 2017
Could the new year present better opportunities for the big pharma? Yes, but challenges remain. Here are three of Pfizer’s biggest risks in 2017.
For 2017, expect gridlock from unexpected places
The interplay between politics and the macro economy has shaped our business environment since 2008, often in adverse ways, and will continue to do so. The last eight years have been marked by a toxic partisan divide between Congress and the president.
Apple, Allergan, Twitter: Doug Kass’ Views
Doug Kass shares his thoughts on his latest ‘Best Ideas’ long and discusses how the market may have reached its Outer Limits. Doug Kass shares his views every day on RealMoneyPro.
This Startup Will Sequence Your DNA, So You Can Contribute To Medical Research
The price to sequence the human genome has dropped from $100 million in 2001 to just a few thousand dollars today. It’s now cheap enough that some people are starting to get sequenced out of sheer curiosity about what they might uncover.
Americans’ 5 Big Fears About Retirement
If you’re among the millions of American workers worrying that retirement may fail to live up to your expectations, you’re not alone.A new study by Transamerica shows that American workers are wrestling with fearsinvolving financial security and health in retirement. If you have similar worries to the respondents to this survey,here are some ways to overcome them.